THROMOCYTOPENIA INDUCED BY VINORELBINE, DOXURUBICIN AND CISPLATIN IN HUMAN CANCER PATIENTS

Cancer is fatal dilemma of human life. During the recently ended 20th century, it was the more feared and in many ways, the most mysterious of the major life threatening diseases of the word. Despite of surprising advancement in applied therapeutics, cancer is still, both in perception and reality, a very real concern of public health. Therefore present retrospective study was aimed to investigate the thrombocytopenia in cancer patients. A total of 60 adult cancer patients selected with non-small cell lung cancer(NSCL), metastatic breast cancer (MBC), and cancer of cervix, with age between 24 71 years (Mean 42.73, SEM±2.). They were divided in to two groups: Group-1 patients on the treatment protocol of Vinorelbine alone and group 2 patients on treatment protocol of Vinorelbine base combinations; Vinorelbine/ Doxorubicin and Vinorelbine/ Cisplatin. The results obtained were statically analyzed. On comparison of overall mean values over time, the insignificant thrombocytopenia observed in the patients on chemotherapy protocol of Vinorelbine alone and Vinorelbine based combination. By an independent comparison of mean values of two group at every week, a significantly thrombocytopenia seen at week 1 in the patients on treatment protocol vinorelbine based combinations. When the mean value observed before therapy compared with that of at week-4 of both of the groups, there was insignificant decrease noted in thrombocyte count. This study has pointed out insignificant differences in the overall thrombocytopenic syndrome observe in both of the chemotherapy protocols. The clinical pharmacist, medical oncologist, and consultant physician, may therefore suggested to select either of the chemotherapy protocol. The therapeutical efficacy is more important while constituting the overall management of a particular neoplasm.